7-Amino-5-(3-thienyl)pyrazolo[1,5-a]pyrimidine | 174859-67-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 7-Amino-5-(3-thienyl)pyrazolo[1,5-a]pyrimidine
• 英文别名: 5-Thiophen-3-ylpyrazolo[1,5-a]pyrimidin-7-amine
• CAS: 174859-67-7
• 化学式: C₁₀H₈N₄S
• 分子量: 216.266
• InChiKey: LLGMQMKWWCNWTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  84.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-Amino-5-(3-thienyl)pyrazolo[1,5-a]pyrimidine 、 potassium thioacyanate 在 dipotassium peroxodisulfate 作用下， 以 乙腈 为溶剂， 以41 %的产率得到3-thiocyanato-5-(thiophen-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine
  参考文献：
  名称：

  K2S2O8-promoted C3-thiocyanation of pyrazole [1,5-a] pyrimidine-7-amines

  摘要：

  DOI：

  10.1016/j.tet.2023.133324

文献信息

• NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1671962A1

  公开（公告）日：2006-06-21

  The compound represented by the general formula (I): wherein, a fused ring AB represents a 5- to 10-membered fused heterocyclic ring; R1 represents (1) a hydrogen atom, (2) a halogen atom, (3) a cyano group, (4) an oxo group, (5) an optionally protected hydroxyl group, (6) an optionally protected carboxyl group, (7) an optionally protected amino group, (8) a cyclic group which may have a substituent (s), (9) an aliphatic hydrocarbon group which may have a substituent (s), or (10) an optionally protected thiol group; n represents 0 or an integer of 1 to 8; provided that n represents an integer of not less than 2, plural R1 are the same or different; a salt thereof, a solvate thereof or a prodrug thereof has a kinase(especially c-Jun N-terminalkinase) inhibitory activity and an inhibitory activity of a function of AP-1 as a transcription factor, it is useful as a preventive and/or therapeutic agent for a for example, a diabetes of metabolic disease, etc., a rheumatoid arthritis of inflammatory, etc.

  化合物的一般式（I）：其中，融合环AB代表一个5-至10-成员的融合杂环；R1代表（1）氢原子，（2）卤素原子，（3）氰基，（4）氧基，（5）可选保护的羟基，（6）可选保护的羧基，（7）可选保护的氨基，（8）可能具有取代基的环状基团，（9）可能具有取代基的脂肪烃基团或（10）可选保护的硫醇基团; n代表0或1至8的整数; 假设n代表不小于2的整数，则复数R1相同或不同;其盐，溶剂化物或前药具有激酶（尤其是c-Jun N末端激酶）抑制活性和AP-1作为转录因子的功能抑制活性，因此可用作预防和/或治疗代谢疾病（例如糖尿病等）和炎症性风湿性关节炎等的药物。
• Novel fused heterocyclic compound and use thereof
  申请人：Yoshizawa Toshio

  公开号：US20070060595A1

  公开（公告）日：2007-03-15

  The compound represented by the general formula (I): wherein, a fused ring AB represents a 5- to 10-membered fused heterocyclic ring; R 1 represents (1) a hydrogen atom, (2) a halogen atom, (3) a cyano group, (4) an oxo group, (5) an optionally protected hydroxyl group, (6) an optionally protected carboxyl group, (7) an optionally protected amino group, (8) a cyclic group which may have a substituent (s), (9) an aliphatic hydrocarbon group which may have a substituent (s), or (10) an optionally protected thiol group; n represents 0 or an integer of 1 to 8; provided that n represents an integer of not less than 2, plural R 1 are the same or different; a salt thereof, a solvate thereof or a prodrug thereof has a kinase (especially c-Jun N-terminal kinase) inhibitory activity and an inhibitory activity of a function of AP-1 as a transcription factor, it is useful as a preventive and/or therapeutic agent for a for example, a diabetes of metabolic disease, etc., a rheumatoid arthritis of inflammatory, etc.

  化合物的一般式(I)表示的化合物：其中，融合环AB表示一个5-至10-成员的融合杂环；R1表示（1）氢原子，（2）卤原子，（3）氰基，（4）氧代基，（5）可选保护的羟基，（6）可选保护的羧基，（7）可选保护的氨基，（8）可能具有取代基（s）的环状基团，（9）可能具有取代基（s）的脂肪烃基团，或（10）可选保护的硫醇基团；n表示0或1至8的整数；但是，如果n表示不少于2的整数，则复数R1相同或不同；其盐、溶剂化物或前药具有激酶（特别是c-Jun N末端激酶）抑制活性和AP-1作为转录因子的功能抑制活性，因此它对于例如代谢性疾病的糖尿病等，炎症性的类风湿性关节炎等的预防和/或治疗剂是有用的。
• PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE
  申请人：OTSUKA PHARMACEUTICAL FACTORY, INC.

  公开号：EP0714898A1

  公开（公告）日：1996-06-05

  The invention provides a pyrazolo[1,5-a]pyrimidine derivative of the following formula (1): wherein R¹ is hydrogen, lower alkyl which may have thienyl, lower alkoxy, lower alkylthio, oxo or hydroxyl as a substituent, cycloalkyl, thienyl, furyl, lower alkenyl, or phenyl which may have 1 to 3 substituents selected from the group consisting of lower alkyl, lower alkoxy, phenylthio and halogen; R² is naphthyl, cycloalkyl, furyl, thienyl, optionally halogen-substituted pyridyl, optionally halogen-substituted phenoxy, or phenyl which may have 1 to 3 substituents selected from the group consisting of lower alkyl, lower alkoxy, halogen, nitro, halogen-substituted lower alkyl, halogen-substituted lower alkoxy, lower alkoxycarbonyl, hydroxyl, phenyl(lower)alkoxy, amino, cyano, lower alkanoyloxy, phenyl and di(lower)alkoxyphosphoryl(lower)alkyl; R³ is hydrogen, phenyl or lower alkyl; R⁴ is hydrogen, lower alkyl, lower alkoxycarbonyl, phenyl(lower)alkyl, optionally phenylthio-substituted phenyl, or halogen; R⁵ is hydrogen or lower alkyl; R⁶ is hydrogen, lower alkyl, phenyl(lower)alkyl, or benzoyl having 1 to 3 substituents selected from the group consisting of lower alkoxy, halogen-substituted lower alkyl and halogen; R¹ and R⁵ may conjointly form lower alkylene; Q is carbonyl or sulfonyl; A is a single bond, lower alkylene or lower alkenylene; and n is 0 or 1. This derivative is useful as a potent analgesic.

  本发明提供了下式（1）的吡唑并[1,5-a]嘧啶衍生物： 其中 R¹ 是氢、可具有噻吩基、低级烷氧基、低级烷硫基、氧代或羟基作为取代基的低级烷基、环烷基、噻吩基、呋喃基、低级烯基或可具有 1 至 3 个选自低级烷基、低级烷氧基、苯硫基和卤素的取代基的苯基；R² 是萘基、环烷基、呋喃基、噻吩基、任选卤素取代的吡啶基、任选卤素取代的苯氧基或苯基，可具有 1 至 3 个取代基，这些取代基可从低级烷基、低级烷氧基、卤素、硝基和卤素组成的组中选出、低级烷氧基、卤素、硝基、卤素取代的低级烷基、卤素取代的低级烷氧基、低级烷氧基羰基、羟基、苯基（低级）烷氧基、氨基、氰基、低级烷酰氧基、苯基和二（低级）烷氧基磷酰（低级）烷基；R³ 是氢、苯基或低级烷基；R⁴ 是氢、低级烷基、低级烷氧基羰基、苯基（低级）烷基、任选的苯硫基取代苯基或卤素；R⁵ 是氢或低级烷基；R⁶ 是氢、低级烷基、苯基（低级）烷基或具有 1 至 3 个取代基的苯甲酰基，取代基可从低级烷氧基、卤素取代的低级烷基和卤素组成的组中选出；R¹ 和 R⁵ 可共同形成低级亚烷基；Q 是羰基或磺酰基；A 是单键、低级亚烷基或低级亚烯基；n 是 0 或 1。这种衍生物可用作强效镇痛剂。
• US5707997A
  申请人：——

  公开号：US5707997A

  公开（公告）日：1998-01-13